Feb 25 (Reuters) - International Personal Finance Plc said on Wednesday its growth in Eastern Europe slowed in the final weeks of 2014 due to intensifying competition from payday lenders and banks, especially in Poland and the Czech Republic.
of information will be Esbriet's U.S. price--if we assume 25% penetration of the 200,000 patients believed to have IPF in the U.S. and Europe combined, as well as an $80,000 U.S. price, peak sales above $3 billion in 2022 are achievable
Esbriet in more severe patients, which represent about a third of IPF patients, even though it was tested in mild to moderate patients in its trials. Considering the lack of approved therapies for IPF in the United States and the severe unmet need among patients
milestone for the company will be the presentation of detailed Phase III results from Esbriet and Boehringer Ingelheim's competing IPF treatment, BIBF-1120, at the American Thoracic Society conference in mid-May. Esbriet revenue grew to $30.3 million
Preliminary Phase III data from Boehringer Ingelheim’s trials of nintedanib in IPF were presented in abstract form prior to their presentation at the American Thoracic Society conference in May. While the abstracts
Phase III ASCEND study in idiopathic pulmonary fibrosis, or IPF --which are expected early next quarter and are necessary for ..... reporting the results of its two Phase III trials for BIBF-1120 in IPF in early 2014, which, if positive, could add competition to
treat idiopathic pulmonary fibrosis, or IPF . The disease causes fatal lung scarring ..... trial to support the efficacy of Esbriet in IPF patients. In our view, the FDA requested ..... 000 people in the U.S. suffer from IPF , and there are currently between 50,000
also weighed on sales growth. However, typically, the sickest patients are prescribed the drug during the initial launch, and we think discontinuations will fall over time as prescriptions reflect the broader mild-to-moderate IPF market.
by-country launch timelines in Europe are causing large swings in InterMune's stock, we think the overall outlook for the IPF drug remains positive. We're keeping our fair value estimate intact, and we believe recent volatility presents investors
for lead drug candidate pirfenidone for the treatment of idiopathic pulmonary fibrosis . Considering the debilitating nature of IPF and the fact that pirfenidone did show efficacy in one of its two Phase III trials , we think there is a high chance the drug